Zuclopenthixol is a first-generation thioxanthene antipsychotic used for schizophrenia and acute psychotic episodes, particularly when management of agitation is a priority. It's more widely used in Europe, Canada, and Australia than in the United States. Like haloperidol, it has notable risk of extrapyramidal symptoms, and CYP2D6 phenotype is the principal pharmacogenetic factor in how strongly those side effects show up.
Acute dystonic reactions need prompt treatment with intramuscular benztropine or diphenhydramine. Neuroleptic malignant syndrome (high fever, muscle rigidity, autonomic instability) is rare but life-threatening and warrants emergency care.
Akathisia, Parkinsonism, and dystonia track with plasma concentration. The higher the zuclopenthixol level, the higher the D2 receptor occupancy, and the higher the risk of movement-related side effects.
Zuclopenthixol is often given as long-acting depot injections (typically every 2 to 4 weeks). If side effects emerge from a depot dose, the drug stays in the system for weeks. This is part of why getting the dose right initially is more important than for oral antipsychotics.
Drugs that inhibit CYP2D6 (fluoxetine, paroxetine, bupropion) reduce zuclopenthixol clearance and can produce a phenocopy of a poor metabolizer. New EPS after starting another medication often points to a CYP2D6 interaction.
CYP2D6 is the dominant enzyme clearing zuclopenthixol. The clinical pattern mirrors haloperidol: poor metabolizers reach substantially higher plasma concentrations and bear higher EPS risk.
CYP2D6 is the principal enzyme that clears zuclopenthixol. Reduced enzyme activity slows clearance, raises plasma levels at any given dose, and increases dose-related side effects.
Poor metabolizers reach markedly higher zuclopenthixol concentrations and have higher EPS rates. DPWG recommends a 25 to 50 percent dose reduction for intermediate metabolizers and roughly 50 percent for poor metabolizers, or selection of an alternative antipsychotic. Ultrarapid metabolizers may have inadequate response at standard doses and need higher dosing or a different drug.
Most useful before initiation of long-acting depot zuclopenthixol, where dose adjustment is slow and getting the initial dose right matters. Also worth considering if EPS or sedation has been disproportionate to dose, or if you've had similar issues on other CYP2D6-metabolized antipsychotics.
Learn how genetics may affect your response to these related medications:
No. Zuclopenthixol is not currently FDA-approved or marketed in the United States. It's used widely in Canada, the United Kingdom, much of Europe, and Australia. Patients receiving zuclopenthixol in the US typically obtained it abroad or have moved between countries.
Acuphase is a short-acting injectable form (zuclopenthixol acetate) used for acute episodes; effect lasts 2 to 3 days. The depot form (zuclopenthixol decanoate) is long-acting and given every 2 to 4 weeks for maintenance. The pharmacogenetic considerations are similar but dose adjustments are easier with acuphase than with the long-acting depot.
Often yes, particularly if you switch from a CYP2D6-cleared drug like zuclopenthixol or haloperidol to one with a different metabolic pathway. Quetiapine, olanzapine, and clozapine have lower EPS risk in general.
Find out how your DNA may influence your response to Zuclopenthixol and other medications with a Gene2Rx pharmacogenetics report.
Get Your Report Try Our Free Calculator